Onglyza Diabetes Drug linked to Heart Failure
An FDA review published April 14, 2015 links the diabetes drug Onglyza to an increased risk of heart failure. Onglyza may also increase the risk of pancreatic cancer. Onglyza (saxagliptin) – co-developed by Bristol